Clear All
777 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA Toremifene Citrate Fareston 60 mg Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Yes 1997 In Use
NA isotretinoin Absorica, Amnesteem, Claravis, Myorisan, Zenatane many Hormonal Therapy Immunomodulator Retinoic Acid Derivative Yes 1982 In Use
NA Crizotinib Xalkori 250 mg Chemotherapy Tyrosine Kinase Inhibitor ALK Yes 2011 In Use
NA Sunitinib malate Sutent 12.5 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR,KIT, RET, CSF Yes 2006 In Use
Vimseltinib Romvimza 14mg, 20mg, 30mg Chemotherapy Tyrosine Kinase Inhibitor CSF1R Yes 2025 In Use
NA Lapatinib Tykerb 250 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Yes 2007 In Use
NA Lenalidomide Revlimid 5 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 2005 In Use
NA Neratinib Nerlynx 40 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Yes 2017 In Use
NA Ibrutinib Imbruvica 140 mg Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Yes 2014 In Use
NA Estradiol Estrace 0.5mg Hormonal Therapy Estrogen Yes 1998 In Use
NA Erlotinib Tarceva 150 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2004 In Use
NA Vandetanib Caprelsa 100 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, EGFR Yes 2011 In Use
Niraparib and Abiraterone Akeega Multiple Chemotherapy Androgen Receptor Inhibitor, Enzyme Inhibitor CYP 17, PARP Yes 2023 In Use
NA Nilotinib Tasigna 200 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2007 In Use
Asciminib Scemblix 20mg,40mg Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Yes 2021 In Use
NA Fluoxymesterone Androxy 10 mg Hormonal Therapy Androgen Yes 1983 In Use
NA Zanubrutinib Brukinsa 80mg Chemotherapy Tyrosine Kinase Inhibitor BTK Yes 2019 In Use
NA venetoclax Venclexta 100 mg Chemotherapy Enzyme Inhibitor BCL-2 Yes 2016 In Use
NA Imatinib mesylate Gleevec 400 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2001 In Use
NA Elacestrant Orserdu Multiple Hormonal Therapy Estrogen Receptor Antagonist ERÉ‘ Yes 2023 In Use
NA Gardasil-9 Human papillomavirus vaccine Ancillary Therapy Protective Agent HPV Vaccine No 2016 In Use
NA Bicalutamide Casodex 50 mg Hormonal Therapy Androgen Receptor Inhibitor non-steriodal Yes 1995 In Use
NA Anagrelide Agrylin 1mg Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Yes 1997 In Use
NA Tepotinib Hydrochloride Tepmetko 225mg Chemotherapy Tyrosine Kinase Inhibitor MET Yes 2021 In Use
NA Palbociclib Ibrance 75 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2015 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.